

Works:
SP-1192, A & B Phase-IV, RIICO
Industrial Area, Distt. Alwar,
Bhiwadi - 301019 (Rajasthan)

Tel.: 07240040011
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/OUTCOME/2022-23

Date: 11.11.2022

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E) Mumbai- 400051

Scrip Code- 531146

Symbol- MEDICAMEQ

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended on September 30, 2022.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended on September 30, 2022 as **Annexure-A** and
- Limited Review Report from Rai Qimat & Associates, Chartered Accountants on the Un- Audited Financial Results (Standalone & Consolidated) as **Annexure-B**
- An Investor release on the financial results is enclosed as **Annexure-C**



The meeting of the Board of Directors commenced on 02.30 p.m. and concluded at 03.30 p.m.

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended on September 30, 2022, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited



Parul Choudhary
Company Secretary
ACS44157



MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Un-audited Standalone and Consolidated Financial Results for the Quarter and Half Year ended as on 30th Sept' 2022

PART I


Rupees in Lacs (Except per Share Data)

| PART I | Particulars | Standalone | | | | | | Consolidated | | | | | | |
|--------|---|--------------------------|-----------------|-----------------|------------------------|-----------------|-----------------|--------------------------|-----------------|-----------------|------------------------|-----------------|-----------------|------------|
| | | Three Month period Ended | | | Six Month Period Ended | | | Three Month period Ended | | | Six Month Period Ended | | | Year Ended |
| | | 30.09.2022 | 30.06.2022 | 30.09.2021 | 30.09.2022 | 30.09.2021 | 31.03.2022 | 30.09.2022 | 30.06.2022 | 30.09.2021 | 30.09.2022 | 30.09.2021 | 31.03.2022 | |
| | Un-audited | Un-audited | Un-audited | Un-audited | Un-audited | Audited | Un-audited | Un-audited | Un-audited | Un-audited | Un-audited | Audited | | |
| 1 | Income from operations | | | | | | | | | | | | | |
| | (a) Net Sales / Income from operations | 3,353.22 | 3,308.80 | 3,252.02 | 6,662.02 | 6,005.05 | 11,544.52 | 3,353.22 | 3,308.80 | 3,252.02 | 6,662.02 | 6,005.05 | 11,544.52 | |
| | (b) Other Income | 52.47 | 96.23 | 47.63 | 148.70 | 55.50 | 172.01 | 52.47 | 96.23 | 47.63 | 148.70 | 55.50 | 172.01 | |
| | (c) Total Revenue | 3,405.70 | 3,405.03 | 3,299.65 | 6,810.73 | 6,060.55 | 11,716.53 | 3,405.69 | 3,405.03 | 3,299.65 | 6,810.72 | 6,060.55 | 11,716.53 | |
| 2 | Expenses | | | | | | | | | | | | | |
| | a) Cost of Material Consumed | 1,956.90 | 1,690.39 | 1,501.23 | 3,647.29 | 2,725.75 | 5,569.07 | 1,956.90 | 1,690.39 | 1,501.23 | 3,647.29 | 2,725.75 | 5,569.07 | |
| | b) Purchase of Goods Traded | | | | | | | | | | | | | |
| | c) Changes in inventory of Finished Goods and Work in Progress | (299.81) | (0.93) | (115.62) | (300.74) | (112.23) | (333.63) | (299.81) | (0.93) | (115.62) | (300.74) | (112.23) | (333.63) | |
| | d) Employees Benefits Expenses | 491.15 | 434.18 | 411.71 | 925.33 | 704.17 | 1,450.19 | 491.15 | 434.18 | 411.71 | 925.33 | 704.17 | 1,450.19 | |
| | e) Finance Cost | 61.60 | 76.72 | 29.97 | 138.32 | 34.38 | 140.06 | 61.60 | 76.72 | 29.97 | 138.32 | 34.38 | 140.06 | |
| | f) Depreciation and Amortisation Expenses | 161.53 | 152.72 | 135.04 | 314.25 | 268.01 | 577.14 | 161.53 | 152.72 | 135.04 | 314.25 | 268.01 | 577.14 | |
| | g) Other expenses | 619.42 | 619.45 | 832.00 | 1,238.87 | 1,460.57 | 2,503.35 | 620.13 | 619.45 | 832.00 | 1,239.58 | 1,460.57 | 2,504.29 | |
| | Total Expenses | 2,990.79 | 2,972.53 | 2,794.33 | 5,963.32 | 5,080.65 | 9,906.18 | 2,991.50 | 2,972.53 | 2,794.33 | 5,964.03 | 5,080.65 | 9,907.11 | |
| 3 | Profit/(Loss) before Exceptional Items & Tax (1 - 2) | 414.91 | 432.50 | 505.32 | 847.41 | 979.90 | 1,810.35 | 414.19 | 432.50 | 505.32 | 846.69 | 979.90 | 1,809.42 | |
| 4 | Exceptional Items (Commercial Tax Expenses Related to Earlier Years) | | | | | | | | | | | | | |
| 5 | Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4) | 414.91 | 432.50 | 505.32 | 847.41 | 979.90 | 1,810.35 | 414.19 | 432.50 | 505.32 | 846.69 | 979.90 | 1,809.42 | |
| 6 | Tax Expenses | | | | | | | | | | | | | |
| | Current Year | 86.16 | 97.88 | 123.03 | 184.03 | 189.06 | 397.69 | 86.16 | 97.88 | 123.03 | 184.03 | 189.06 | 397.69 | |
| | MAT Credit Entitlement | | | | | | | | | | | | | |
| | Deferred Tax Liability | (32.37) | (23.93) | (39.89) | (56.30) | (46.48) | (77.98) | (32.37) | (23.93) | (39.89) | (56.30) | (46.48) | (77.98) | |
| | Total Tax Expense | 53.79 | 73.94 | 83.14 | 127.73 | 142.58 | 319.71 | 53.79 | 73.94 | 83.14 | 127.73 | 142.58 | 319.71 | |
| 7 | Net Profit /Loss for the period from Continuing operation (5- 6) | 361.12 | 358.56 | 422.18 | 719.68 | 837.32 | 1,490.64 | 360.40 | 358.56 | 422.18 | 718.96 | 837.32 | 1,489.71 | |
| 8 | Other Comprehensive Income | | | | | | | | | | | | | |
| 9 | Total Comprehensive Income net of Tax | 361.12 | 358.56 | 422.18 | 719.68 | 837.32 | 1,490.64 | 360.40 | 358.56 | 422.18 | 718.96 | 837.32 | 1,489.71 | |
| 10 | Paid up equity share capital (Rs. 10/- per share) | 1,265.11 | 1,221.66 | 1,221.66 | 1,265.11 | 1,221.66 | 1,221.66 | 1,265.11 | 1,221.66 | 1,221.66 | 1,265.11 | 1,221.66 | 1,221.66 | |
| 11 | Earning Per Share (Rs.) | | | | | | | | | | | | | |
| | Basic | 2.85 | 2.94 | 3.46 | 5.69 | 6.85 | 12.20 | 2.85 | 2.94 | 3.46 | 5.68 | 6.85 | 12.19 | |
| | Diluted | 2.85 | 2.94 | 3.46 | 5.69 | 6.85 | 12.20 | 2.85 | 2.94 | 3.46 | 5.68 | 6.85 | 12.19 | |

NOTES :

- 1 The Un-audited financial results for the quarter and half year ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11.11.2022
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- 4 The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 "Earning per Share"
- 5 The results are not comparable on quarterly or yearly basis as company is regularly incurring capex and filling dossiers with regulatory authorities which is visible from increased finance cost. The company has also recruited and placed senior human resources for the purpose of creating its own marketing network in francophone Africa. The company shall start reaping its benefits from next financial year.
- 6 Limited review report has been carried out by the Statutory Auditors for the above period.
- 7 The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For & on behalf of Board of Directors
Medicamen Biotech Limited


 (Rahul Bishnoi)
 Chairman

Place : New Delhi
Dated : 11.11.2022

MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019


CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

| STATEMENT OF ASSETS & LIABILITIES | | | | |
|---|------------------------------------|---------------------------------|------------------------------------|---------------------------------|
| All Figures in Rs. Lacs | | | | |
| Particulars | Standalone | | Consolidated | |
| | As at Sep 30,2022 Un-audited | As at Mar 31,2022 Audited | As at Sep 30,2022 Un-audited | As at Mar 31,2022 Audited |
| A ASSETS | | | | |
| 1 Non-current assets | | | | |
| (a) Property, Plant and Equipment | 9,253.05 | 9,211.73 | 9,254.00 | 9,211.73 |
| (b) Intangible assets | 43.87 | 35.98 | 43.87 | 35.98 |
| (c) Capital work-in-progress | - | - | - | - |
| (d) Financial Assets : Investments | 407.65 | 206.14 | - | - |
| (e) Financial Assets : Loans and advances | 108.14 | 86.52 | 108.14 | 86.52 |
| (f) Deferred Tax Assets (Net) | 105.94 | 49.64 | 105.94 | 49.64 |
| (g) Other Non- current assets | 1,040.25 | 881.69 | 1,061.02 | 881.70 |
| Total Non-current Assets | 10,958.90 | 10,471.70 | 10,572.97 | 10,265.57 |
| 2 Current assets | | | | |
| (a) Inventories | 2,884.84 | 2,700.97 | 2,884.84 | 2,700.97 |
| (b) Financial Assets | | | | |
| (i) Current investments | - | - | - | - |
| (ii) Trade receivables | 6,539.27 | 6,117.85 | 6,729.87 | 6,322.36 |
| (iii) Cash and Bank Balances | 2,854.48 | 381.49 | 3,055.02 | 382.48 |
| (iv) Loans and advances | 401.85 | 526.38 | 401.85 | 526.38 |
| (c) Other current assets | 2,211.21 | 2,371.61 | 2,221.68 | 2,371.61 |
| Total current Assets | 14,891.65 | 12,098.30 | 15,293.26 | 12,303.80 |
| Total Assets | 25,850.55 | 22,570.00 | 25,866.23 | 22,569.37 |
| B EQUITY AND LIABILITIES | | | | |
| 1 Equity | | | | |
| (a) Equity share capital | 1,265.11 | 1,221.66 | 1,265.11 | 1,221.66 |
| (b) Other Equity | 17,451.51 | 13,582.12 | 17,315.64 | 13,425.32 |
| Total Equity | 18,716.62 | 14,803.78 | 18,580.75 | 14,646.98 |
| LIBILITIES | | | | |
| 2 Non-current Liabilities | | | | |
| (a) Financial Liabilities : Borrowings | 94.32 | 507.36 | 94.32 | 507.36 |
| (b) Provisions | 193.25 | 145.94 | 193.25 | 145.94 |
| (c) Deferred Tax liabilities (Net) | - | - | - | - |
| Total Non-current Liabilities | 287.57 | 653.30 | 287.57 | 653.30 |
| 3 Current Liabilities | | | | |
| (a) Financial Liabilities | | | | |
| (i) Borrowings | 2,754.57 | 1,927.49 | 2,754.57 | 1,927.49 |
| (ii) Trade payables | 3,749.18 | 4,173.83 | 3,894.85 | 4,330.00 |
| (b) Other current liabilities | 140.58 | 502.90 | 142.01 | 502.90 |
| (c) Provisions | 18.00 | 82.32 | 22.45 | 82.32 |
| (c) Current Tax Liabilities (Net) | 184.03 | 426.38 | 184.03 | 426.38 |
| Total Current Liabilities | 6,846.36 | 7,112.92 | 6,997.91 | 7,269.09 |
| Total Equity and Liabilities | 25,850.55 | 22,570.00 | 25,866.23 | 22,569.37 |

For & on behalf of Board of Directors
Medicamen Biotech Limited

R. Bishnoi
(Rahul Bishnoi)
Chairman



Place : New Delhi
Dated : 11.11.2022

MEDICAMEN BIOTECH LIMITED

1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594


STANDALONE CASH FLOW STATEMENT FOR THE PERIOD 01.04.2022 TO 30.09.2022

| Particulars | For the year ended 30 th Sept, 2022 | For the year ended 31st March, 2022 | For the year ended 30 th Sept, 2022 | For the year ended 31st March, 2022 |
|--|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| <u>CASH FLOW FROM OPERATING ACTIVITIES</u> | | | | |
| Net Profit/(Loss) after tax from continuing operations | 719.68 | 1,490.64 | 718.96 | 1,489.71 |
| Non-cash adjustment to reconcile profit before tax to net cash flows | | | | |
| Provision for Taxation | 184.03 | 397.69 | 184.03 | 397.69 |
| Adjustment for Deferred Tax | -56.30 | -77.98 | -56.30 | -77.98 |
| Financial Charges | 138.32 | 140.06 | 138.32 | 140.06 |
| Loss/(profit) on sale of fixed assets | - | -0.12 | - | -0.12 |
| Depreciation/amortization on continuing operation | 314.25 | 577.14 | 314.25 | 577.14 |
| Interest income | 0.18 | -13.54 | 0.18 | -13.54 |
| Operating profit before working capital changes | 1,300.16 | 2,513.89 | 1,299.44 | 2,512.96 |
| Movement of working capital | | | | |
| Increase/(decrease) in trade payables | -424.65 | 1,216.19 | -435.15 | 1,108.86 |
| Increase / (decrease) in long-term provisions | 47.31 | 30.39 | 47.31 | 30.39 |
| Increase / (decrease) in short-term provisions | -490.70 | -366.54 | -486.25 | -411.98 |
| Increase/(decrease) in other current liabilities | -240.15 | 3.78 | -238.72 | 12.48 |
| Decrease/(increase) in trade receivables | -421.42 | -1,142.50 | -407.51 | -1,067.61 |
| Decrease/(increase) in inventories | -183.87 | -2,180.59 | -183.87 | -2,180.59 |
| Decrease / (increase) in long-term loans and advances | -21.62 | -8.98 | -21.62 | -8.98 |
| Decrease / (increase) in short-term loans and advances | 124.53 | 187.57 | 124.53 | 507.57 |
| Decrease/(increase) in other current assets | 265.40 | 673.53 | 254.93 | 353.53 |
| Decrease/(increase) in other Non-current assets | -158.56 | -125.73 | -179.32 | -125.73 |
| Direct taxes paid | -105.00 | -320.00 | -105.00 | -320.00 |
| Net cash flow from/ (used in) operating activities (A) | -308.57 | 481.01 | -331.23 | 410.90 |
| <u>CASH FLOWS FROM INVESTING ACTIVITIES</u> | | | | |
| Purchase of fixed assets including intangible & CWIP | -363.46 | -860.82 | -364.41 | -860.82 |
| Purchase of non-current investments | -201.51 | - | - | - |
| Interest received | -0.18 | 13.54 | -0.18 | 13.54 |
| Net cash flow from/(used in) investing activities (B) | -565.15 | -847.28 | -364.59 | -847.28 |
| <u>CASH FLOWS FROM FINANCING ACTIVITIES :</u> | | | | |
| Proceeds from issuance of share capital | 43.45 | - | 43.45 | - |
| Proceeds from Securities Premium | 3,037.16 | - | 3,037.16 | - |
| Capital Reserve | - | - | 21.65 | -9.52 |
| Shares Warrants | 112.55 | - | 112.55 | - |
| Long-term borrowings net of repayment | -413.04 | -133.10 | -413.04 | -133.10 |
| Proceeds from short-term borrowings | 827.08 | 834.65 | 827.08 | 834.65 |
| Interest paid | -138.32 | -140.06 | -138.32 | -140.06 |
| Dividends paid on equity shares | -122.17 | -122.17 | -122.17 | -122.17 |
| Net cash flow from/(used in) in financing activities (C) | 3,346.71 | 439.32 | 3,368.36 | 429.80 |
| Net increase/(decrease) in cash and cash equivalents (A + B + C) | 2,472.99 | 73.05 | 2,672.54 | -6.58 |
| Cash and cash equivalents at the beginning of the year | 381.49 | 308.44 | 382.48 | 389.06 |
| Cash and cash equivalents at the end of the year | 2,854.48 | 381.49 | 3,055.02 | 382.48 |

For & on behalf of Board of Directors
Medicamen Biotech Limited

R. Bishnoi

(Rahul Bishnoi)
Chairman



Place : New Delhi
Dated : 11.11.2022

RAI QIMAT & ASSOCIATES
CHARTERED ACCOUNTANTS



**LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY AND YEAR-TO-DATE
 STANDALONE FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER
 REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE
 REQUIREMENTS) REGULATIONS, 2015**

To

The Board of Directors,
Medicamen Biotech Ltd.
 1506, Chiranjiv Tower, 43,
 Nehru Place New Delhi-110019


We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and half year ended September 30, 2022 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates
 (Chartered Accountants)


 CA Qimat Raj Garg
 (Partner)

Membership Number: 080857
 UDIN: 22080857BCUEGW8716

Place: Gurugram
 Date: 11.11.2022



LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY AND YEAR-TO-DATE CONSOLIDATED FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To


The Board of Directors,
Medicamen Biotech Limited
1506, Chiranjiv Tower 43,
Nehru Place, New Delhi- 110019

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of MEDICAMEN BIOTECH LIMITED ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associate for the quarter and half year ended September 30, 2022 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. The Statement includes the results of the Opal Pharmaceuticals Pty. Ltd & Medicamen Life Sciences Pvt. Ltd. (the "Subsidiary" Companies)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7(ii) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.



Our conclusion on the Statement is not modified in respect of the above matter.

For Rai Qimat & Associates
(Chartered Accountants)


GURU
CA Qimat Rai Garg
(Partner)

Membership Number: 080857
UDIN: 22080857BCUEKZ8833

Place: Gurugram
Date: 11.11.2022



Medicamen Biotech Limited

Investor Presentation Sep 2022



Business Review and Strategy



Medicamen Forays in Domestic Market with CVD




Domestic Oncology Product Range

Business Review and Strategy

- Received [ANVISA Brazil](#) approval for general capsules and PFS section. Now all 4 dosages forms namely Tablets, Capsule, Liquid Oral and PFS are approved with [ANVISA Brazil](#) for Bhiwadi Plant. MBL starts to file dossiers for these lines.
- The Bhiwadi plant was inspected by EU Authority in September 2022. No critical observation was reported.
- The process of filing the 100 dossiers in 10 Francophone countries is in full swing. The company has already started receiving product registrations. 15 product registration completed in Ghana.
- The finalization of distribution arrangement is in final stage.
- Filed 20 more dossiers in Ethiopia. Received 7 more product registration in Ethiopia, making total of 30 registered products which will enhance the current business profile.
- Successfully completed three validation batches of Bortozimib 3.5mg Injectable for US Market. The product is under stability for six months.

Medicamen Forays in Domestic Market with CVD

- 
- MBL is foraying into Domestic business with its subsidiary Medicamen Life Sciences Pvt Ltd. Vision of the Company is to become a most admired Pharmaceuticals organizations by offering research & data backed, affordable & quality medicines for Indian populations. To start with, the Company has entered Cardio-vascular & Diabetes (CVD) Business.
 - 33 products of CVD launched in India through its subsidiary Medicamen Life Sciences Pvt. Ltd., and more products are in pipeline.

Domestic Product Range

Diabetic

Brand Name

Product

| | |
|-------------------|--------------------------------------|
| Sitawow 50 | Sitagliptin 50 mg |
| Sitawow 100 | Sitagliptin 100 mg |
| Sitawow M 50/1000 | Sitagliptin 50 + Metformin 1000 mg |
| Sitawow 50/500 | Sitagliptin 50 + Metformin 500 mg |
| Dapica S 5/50 | Sitagliptin 50 + Dapagliflozin 5 mg |
| Dapica S 10/100 | Sitagliptin 100+ Dapagliflozin M10 g |
| Dapica 5 | Dapagliflozin 5 mg |
| Dapica 10 | Dapagliflozin 10 mg |
| Dapica M 10/500 | Dapagliflozin 10 + Metformin 500 |
| Dapica M 10/1000 | Dapagliflozin 10 + Metformin 1000 |
| Repvog .3/.5 | Voglibose 0.3+ Repaglinide .5 |
| Repvog0.3/1 | Voglibose 0.3+ Repaglinide 1 |
| Repvog0.3/2 | Voglibose 0.3+ Repaglinide 2 |



Domestic Product Range

Hypertension

Brand Name

Product

| | |
|--------------------|--------------------------------|
| Affotel 20 | Telmisartan 20 mg |
| Affotel 40 | Telmisartan 40 mg |
| Affotel 80 | Telmisartan 80 mg |
| Affitel AM 40/5 | Telmisartan 40+ Amlodipine 5mg |
| Affotel CT 40/6.25 | Telmisartan 40 + CTD 6.25 |
| Affotel CT40/12.5 | Telmisartan 40 + CTD 12.5 |
| Affotel Beta | Telmisartan 40+ Metoprolol 50 |
| Affobis 1.25 | Bisoprolol 1.25 mg |
| Affobis 2.5 | Bisoprolol 2.5 mg |
| Affobis 5 | Bisoprolol 5 mg |



Domestic Product Range

Cardio-vascular

Brand Name Product

| | |
|----------------|---|
| Roswow 10 | Rosuvastatin 10 mg |
| Roswow20 | Rosuvastatin 20 mg |
| Roswow Gold 10 | Rosuvastatin 10 + ASP 75 + Clopidogrel 75 |
| Roswow Gold 20 | Rosuvastatin 20 + ASP 75 + Clopidogrel 75 |
| Roswow CV 10 | Rosuvastatin 10+ Clopidogrel 75 |
| Roswow A 10 | Rosuvastatin 10+ Asprin 75 |
| Roswow 20 A | Rosuvastatin 20 + Asprin 75 |
| Roswow CV 20 | Rosuvastatin 20+ Clopidogrel 75 |
| Roswow F 10 | Rosuvastatin 10+ Finofibrate 160 |
| Roswow F 20 | Rosuvastatin 20+ Finofibrate 160 |



Domestic Oncology Product Range



Domestic Oncology Product Range





MB Medicamen Biotech Limited

Registered Office:

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi- 110019

Phone: 011-47589500

E-mail: cs@medicamen.com

Website: www.medicamen.com